Lara Iglesias
Overview
Explore the profile of Lara Iglesias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, et al.
Eur J Cancer
. 2025 Jan;
216:115122.
PMID: 39793445
Purpose: MAK683, a first-in-class and highly selective allosteric inhibitor of the embryonic ectoderm development subunit of polycomb repressive complex 2, has shown sustained antitumor activity in tumor xenograft models. This...
2.
Losa F, Fernandez I, Etxaniz O, Gimenez A, Gomila P, Iglesias L, et al.
Clin Transl Oncol
. 2022 Mar;
24(4):681-692.
PMID: 35320504
Cancer of unknown primary site (CUP) is defined as a heterogeneous group of tumors that appear as metastases, and of which standard diagnostic work-up fails to identify the origin. It...
3.
Falco A, de Oliveira T, Cacicedo J, Ospina A, Ticona M, Galindo H, et al.
Cancer Manag Res
. 2021 Sep;
13:6689-6703.
PMID: 34471383
Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at...
4.
Fernandez-Mateos J, Perez-Garcia J, Seijas-Tamayo R, Mesia R, Rubio-Casadevall J, Garcia-Giron C, et al.
Sci Rep
. 2020 Oct;
10(1):16634.
PMID: 33024167
234 diagnostic formalin-fixed paraffin-embedded (FFPE) blocks from homogeneously treated patients with locally advanced head and neck squamous cell carcinoma (HNSCC) within a multicentre phase III clinical trial were characterised. The...
5.
Agullo-Ortuno M, Garcia-Ruiz I, Diaz-Garcia C, Enguita A, Pardo-Marques V, Prieto-Garcia E, et al.
Cancer Chemother Pharmacol
. 2019 Dec;
85(3):525-535.
PMID: 31832811
Purpose: Therapeutic options for cancer patients have increased in the last years, although drugs resistance problem remains unresolved. Genetic background in individual susceptibility to cancer treatment could influence the therapy...
6.
Agullo-Ortuno M, Gomez-Martin O, Ponce S, Iglesias L, Ojeda L, Ferrer I, et al.
Clin Lung Cancer
. 2019 Sep;
21(1):75-85.
PMID: 31562055
Background: Immunotherapy is a promising cancer treatment, but surrogate biomarkers of clinical efficacy have not been fully validated. The aim of this work was to evaluate several biomarkers as predictors...
7.
Matias-Guiu X, Fuste V, Iglesias L, Balana C, Concha A, de la Cruz-Merino L, et al.
Rev Esp Patol
. 2018 Dec;
52(1):33-44.
PMID: 30583830
Cancer of unknown primary is defined as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They differ from...
8.
Zugazagoitia J, Rueda D, Carrizo N, Enguita A, Gomez-Sanchez D, Diaz-Serrano A, et al.
Clin Lung Cancer
. 2017 Aug;
19(1):65-73.e7.
PMID: 28780976
Introduction: A substantial fraction of non-small-cell lung cancers (NSCLCs) harbor targetable genetic alterations. In this study, we analyzed the feasibility and clinical utility of integrating a next-generation sequencing (NGS) panel...
9.
Zugazagoitia J, Diaz A, Jimenez E, Nunez J, Iglesias L, Ponce-Aix S, et al.
Front Med (Lausanne)
. 2017 Apr;
4:36.
PMID: 28424775
Dacomitinib is a second-generation, irreversible, covalent pan-HER tyrosine-kinase inhibitor (TKI). It showed potent EGFR signaling inhibition in experimental models, including first-generation TKI-resistant non-small cell lung cancer (NSCLC) cell lines. This...
10.
Rodriguez Garzotto A, Diaz-Garcia C, Agudo-Lopez A, Prieto Garcia E, Ponce S, Lopez-Martin J, et al.
Med Oncol
. 2016 Aug;
33(10):105.
PMID: 27568331
Tumor angiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer. However, no biomarkers have been described as predictors of response to antiangiogenic therapy in these...